Updated Jul 16, 2026
Mathew Aby J. has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.01M.
Aby J. Mathew is the Executive Vice President and Chief Scientific Officer at BioLife Solutions Inc, a company specializing in bioproduction products and services for the cell and gene therapy industry. He has been involved in multiple SEC filings related to his role at the company.
| Role | EVP & Chief Scientific Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-13 | BLFS | BIOLIFE SOLUTIONS INC | F — Tax withholding / forfeiture | 516 | $27.79 | $14K |
| 2026-06-22 | BLFS | BIOLIFE SOLUTIONS INC | F — Tax withholding / forfeiture | 564 | $26.04 | $15K |
| 2026-06-10 | BLFS | BIOLIFE SOLUTIONS INC | F — Tax withholding / forfeiture | 627 | $26.10 | $16K |
| 2026-04-10 | BLFS | BIOLIFE SOLUTIONS INC | F — Tax withholding / forfeiture | 515 | $19.27 | $10K |
| 2026-03-23 | BLFS | BIOLIFE SOLUTIONS INC | F — Tax withholding / forfeiture | 2.3K | $19.12 | $43K |
| 2026-03-05 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 529 | $20.74 | $11K |
| 2026-02-26 | BLFS | BIOLIFE SOLUTIONS INC | F — Tax withholding / forfeiture | 15.6K | $22.65 | $353K |
| 2026-02-26 | BLFS | BIOLIFE SOLUTIONS INC | A — Grant or award | 39.6K | — | |
| 2026-02-26 | BLFS | BIOLIFE SOLUTIONS INC | A — Grant or award | 20.1K | — | |
| 2025-10-09 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale | 509 | $27.36 | $14K |
| 2025-09-11 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale | 630 | $26.83 | $17K |
| 2025-08-26 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale | 531 | $25.44 | $14K |
| 2025-07-07 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale | 536 | $22.27 | $12K |
| 2024-12-19 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 13.2K | $27.16 | $358K |
| 2024-12-19 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 7.6K | $27.33 | $208K |
| 2024-11-29 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 523 | $27.20 | $14K |
| 2024-11-19 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 17.6K | $20.05 | $353K |
| 2024-11-19 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 15.0K | $21.17 | $318K |
| 2024-11-19 | BLFS | BIOLIFE SOLUTIONS INC | S — Open-market sale [10b5-1] | 10.0K | $21.16 | $212K |
| 2024-11-19 | BLFS | BIOLIFE SOLUTIONS INC | M — Option exercise [10b5-1] | 10.0K | $2.06 | $21K |
Aby J. Mathew is the Executive Vice President and Chief Scientific Officer at BioLife Solutions Inc, a company specializing in bioproduction products and services for the cell and gene therapy industry. He has been involved in multiple SEC filings related to his role at the company.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 15 open-market sales ($2.01M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Mathew Aby J. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.